Search clinical trials for: Bosutinib

Total 76 results

Pfizer

Completed

Palatability (Taste) of Oral Formulations of Bosutinib

CML

Belgium
Pfizer

Completed

Evaluation of the Relative Bioavailability of Bosutinib Capsules Under Fed Condition and Estimation of Food Effect on Orally Administered Bosutinib Capsule

Healthy Participants

Belgium
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Comparing Two Different Tablet Formulations Of Bosutinib

Healthy

United States
Pfizer

Completed

Bioequivalence Study of Bosutinib Pediatric Capsule Relative to Commercial Tablet Under Fed Condition

Healthy Participants

Netherlands
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Comparing Two Different Tablet Formulations Of Bosutinib Under Fed Conditions

Healthy

United States
Pfizer

Completed

Absolute Bioavailability Of Bosutinib

Healthy

United Kingdom
Kyoto University
Pfizer; Kitasato University; Tokushima University; Tottori University

Recruiting

iPSC-based Drug Repurposing for ALS Medicine (iDReAM) Study

Amyotrophic Lateral Sclerosis

Japan
Pfizer

Completed

Study Evaluating SKI-606 (Bosutinib) In Advanced Malignant Solid Tumors

Neoplasms

United States
Children's Oncology Group
Pfizer; Erasmus Medical Center; Dutch Childhood Oncology Group; Innovative Therapies...

Active, not recruiting

Bosutinib in Pediatric Patients With Newly Diagnosed Chronic Phase or Resistant/Intolerant Ph + Chronic Myeloid Leukemia

Accelerated Phase Chronic Myelogenous Leukemia | Chronic Phase Chronic Myelogenous Leukemia | Blastic Phase Chronic Myelogenous Leukemia | Philadelphia Chromosome Positive CML

United States
Pfizer

Completed

Bosutinib In Subjects With Renal Impairment

Renal Insufficiency, Chronic | Renal Insufficiency, Acute | Renal Disease, End-Stage

United States
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study to Determine the Effect of a High-Fat Meal on the Relative Bioavailability and Pharmacokinetics of a Single Dose of Bosutinib Administered Orally to Healthy Subjects

Healthy Subjects

United States
Pfizer

Recruiting

Safety And Efficacy Of Bosutinib (BLF)

Chronic Myelogenous Leukemia

Japan
Pfizer

Completed

Retrospective Observational Research Study to Describe the Real World Use of Bosutinib in a Single Centre in Scotland

Myeloid Leukemia

United Kingdom
Pfizer

Completed

Bioavailability of Bosutinib Administered as Capsule Contents Mixed With Applesauce or Yogurt Relative to Intact Capsules Under Fed Condition

Healthy Participants

Belgium
Pfizer

Completed

Bosutinib Treatment Extension Study Only For Subjects With Chronic Myeloid Leukemia (CML) Who Have Previously Participated In Bosutinib Studies B1871006 Or B1871008

Chronic Myeloid Leukemia

United States, Canada, Spain, China, Australia, Singapore, Korea, Republic of, France, Hong Kong, Netherlands, Turkey, Poland, Japan, United Kingdom, Argentina, Colombia, Hungary, Russian Federation, South Africa, Belgium, Brazil, Chil... and more
Pfizer

Completed

Study of Bosutinib in Japanese Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Leukemia, Chronic Myelogenous

Japan
Pfizer
pH Associates

Completed

A Study To Describe The Real World Use Of Bosutinib In The UK And Netherlands

Chronic Myeloid Leukaemia

United Kingdom
Pfizer

Completed

Bosutinib For Autosomal Dominant Polycystic Kidney Disease

Polycystic Kidney, Autosomal Dominant

United States, Canada, Australia, Sweden, Spain, Poland, Korea, Republic of, Switzerland, United Kingdom, Moldova, Republic of, Italy, Czech Republic, Hungary, Lithuania, Romania, Slovakia, Turkey
Massachusetts General Hospital
Pfizer; Dana-Farber Cancer Institute; Brigham and Women's Hospital

Completed

Bosutinib in Adult Patients With Recurrent Glioblastoma

Glioblastoma

United States
Georgetown University
Alzheimer's Association

Completed

Impact of Bosutinib on Safety, Tolerability, Biomarkers and Clinical Outcomes in Dementia With Lewy Bodies

Dementia With Lewy Bodies

United States
PETHEMA Foundation

Completed

CML Treated With Bosutinib After Relapse (BOSTRO)

Chronic Myeloblastic Leukaemia

Spain
Pfizer

Completed

Study Evaluating SKI-606 (Bosutinib) In Subjects With Breast Cancer

Breast Neoplasms | Neoplasm Metastasis

United States, Ukraine, Russian Federation, Hong Kong, France, Australia, Poland, Malta
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating The Pharmacokinetics (PK) And Safety Of Bosutinib In Subjects With Liver Disease And In Healthy Subjects

Breast Cancer | Leukemia, Myeloid, Chronic

Poland
Pfizer

Completed

Bioequivalence And Food Effect Study Of Bosutinib In Healthy Subjects

Philadelphia Chromosome Positive (Ph+) Chronic Myeloid Leukemia (CML)

Singapore
Gruppo Italiano Malattie EMatologiche dell'Adulto

Active, not recruiting

Bosutinib in Elderly Chronic Myeloid Leukemia (BEST)

Chronic Myeloid Leukemia

Italy
University of Bonn
Pfizer; RWTH Aachen University; Ludwig-Maximilians - University of Munich; Heidelberg... and other collaborators

Unknown

Phase II Study Testing the Tolerability and the Efficacy of Bosutinib in Chronic Phase CML Patients (BODO)

Chronic Myelogenous Leukaemia

Germany
Pfizer
Developmental Therapeutics Consortium

Terminated

Safety And Efficacy Study Of Bosutinib In Patients With Philadelphia Chromosome Positive Chronic Myeloid Leukemia Previously Treated With One Or More Tyrosine Kinase Inhibitors

Previously Treated PH + CML

Spain, United States, Austria, Sweden, Germany, France, Italy, Norway
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Effect of Rifampin on Bosutinib When Both Are Given to Healthy People

Healthy
Novartis Pharmaceuticals

Active, not recruiting

Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs

Chronic Myelogenous Leukemia

United States, United Kingdom, Hungary, Japan, Saudi Arabia, Australia, Germany, Canada, France, Netherlands, Spain, Lebanon, Turkey, Korea, Republic of, Argentina, Brazil, Bulgaria, Czechia, Israel, Italy, Mexico, Romania, Russian... and more
Neurological Associates of West Los Angeles
Pfizer

Enrolling by invitation

Study for the Use of TKIs for Treatment of Cognitive Decline Due to Degenerative Dementias

Dementia | Mild Cognitive Impairment

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI); Pfizer

Terminated

Bosutinib in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase After Frontline TKI Failure

Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Blasts Under 15 Percent of Bone Marrow Nucleated Cells | Blasts Under 15 Percent of Peripheral Blood White Cells | Blasts Under 30 Percent of Bone Marrow Nucleated Cells | Blasts Under 30 Percent of Peripheral Blood White Cells

United States
Pfizer

Completed

Study Evaluating SKI-606 (Bosutinib) In Philadelphia Chromosome Positive Leukemias

Chronic Myeloid Leukemia

United States, Spain, Australia, Canada, Hong Kong, Singapore, United Kingdom, Germany, Netherlands, Chile, India, South Africa, Sweden, Peru, Argentina, Italy, Austria, Colombia, Brazil, China, Finland, Hungary, Korea, Republic of, M... and more
Pfizer

Completed

Study Evaluating SKI-606 (Bosutinib) In Japanese Subjects With Philadelphia Chromosome Positive Leukemias

Chronic Myelogenous Leukemia

Japan
University of Milano Bicocca
IRCCS San Raffaele

Completed

Allogeneic Stem Cell Transplantation in Chronic Myeloid Leukemia Failing TKIs Therapy

Leukemia | BCR-ABL Positive | Myelogenous | Chronic

Italy
Beijing Pearl Biotechnology Limited Liability Company

Completed

Study of a c-Met Inhibitor PLB1001 in Patients With PTPRZ1-MET Fusion Gene Positive Recurrent High-grade Gliomas

Glioma

China
Beijing Pearl Biotechnology Limited Liability Company

Completed

First-in-human Phase I Study of a Selective c-Met Inhibitor PLB1001

Non-Small Cell Lung Cancer

China
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating Ascending Single-Dose Of Bosutinib Administered With Multiple Doses Of Ketoconazole To Healthy Subjects

Leukemia | Breast Cancer | Tumors

Netherlands
Beijing Pearl Biotechnology Limited Liability Company

Recruiting

A Study of PLB1001 in Non-small Cell Lung Cancer With c-Met Dysregulation(KUNPENG) (KUNPENG)

Non-small Cell Lung Cancer

China
St. Olavs Hospital
Odense University Hospital; Oslo University Hospital; University Hospital of... and other collaborators

Recruiting

Long-acting Low Dose Ropeginterferon for Chronic Myeloid Leukemia Treated With Bosutinib From Diagnosis (BosuPeg)

Chronic Myeloid Leukemia

Norway, Denmark, Finland, Sweden
Fundacion Espanola para la Curacion de la Leucemia...
Pfizer; Roche Farma, S.A

Terminated

Safety and Efficacy Evaluation of Bosutinib Plus Atezolizumab in Newly Diagnosed Chronic Leukemia Adult Patients

Chronic Phase-Chronic Myeloid Leukemia

Spain
Pfizer

Completed

A Drug Interaction Study Between Bosutinib And Aprepitant In Healthy Volunteers

Healthy

United States
Astellas Pharma Global Development, Inc.
Basilea Pharmaceutica International Ltd

Completed

Study of the Effect of Renal Impairment on the Pharmacokinetics of Isavuconazole.

Healthy Volunteers | Pharmacokinetics of Isavuconazole | Renal Impaired

United States
Avistone Biotechnology Co., Ltd.

Recruiting

Vebreltinib Plus PLB1004 in EGFR-mutated, Advanced NSCLC With MET Amplification or MET Overexpression Following EGFR-TKI

Non-Small-Cell Lung Cancer

China
Pfizer

Terminated

Study Of Bosutinib With Capecitabine In Solid Tumors And Locally Advanced Or Metastatic Breast Cancer

Advanced Breast Cancer (Parts 1 and 2) | Advanced Pancreatic Cancer (Part 1) | Advanced Colorectal Cancer (Part 1) | Advanced Cholangiocarcinoma (Part 1) | Advanced Glioblastoma Multiforme (Part 1)

United States, Spain, Hong Kong, Belgium, Australia, France
Baylor College of Medicine

Recruiting

Safety And Efficacy Of TKI Cessation For CML Patients With Stable Molecular Response In A Real World Population (TOKIN)

Chronic Myeloid Leukemia | Chronic Myeloid Leukemia, BCR/ABL-Positive, in Remission | Chronic Myeloid Leukemia in Remission

United States
Pfizer

Completed

A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Leukemia, Myelogenous, Chronic, Breakpoint Cluster Region-Abelson Proto-oncogene (BCR-ABL) Positive

France, United States, Canada, Spain, Czechia, Singapore, Thailand, Denmark, Norway, Korea, Republic of, Finland, Hungary, Sweden, Netherlands, Italy, Germany, Ukraine, South Africa, Taiwan, Australia, Belgium, Israel, Mexico, Poland, S... and more
Apollomics Inc.

Recruiting

A Study Comparing Two Different Capsules, APL-101 and PLB-1001 Capsules, in Healthy Chinese and Caucasian Participants

Bioequivalence

New Zealand
Apollomics Inc.

Recruiting

APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors (SPARTA)

Gastric Cancer | Pancreatic Cancer | NSCLC | Lung Cancer | Brain Tumor | Glioblastoma Multiforme | Advanced Cancer | Colon Cancer | Solid Tumors | Thyroid Cancer | Renal Cancer | Gastroesophageal Junction Adenocarcinoma | EGFR Gene Mutation | MET Amplification | HGF | MET Alteration | MET Fusion | Exon 14 Skipping

United States, Spain, France, United Kingdom, Taiwan, Australia, Finland, Italy, Singapore, Hungary, Canada, Puerto Rico, Russian Federation
Pfizer

Not yet recruiting

A Study to Learn About the Study Medicine Bosulif in Adult Patients With Chronic Myeloid Leukemia(CML).

Chronic Leukemia Myelogenous
Nagla Abdel Karim

Completed

Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors

Carcinoma, Non-Small-Cell Lung | Ovarian Cancer | Thymoma | Mesothelioma | Bladder Cancer | Peritoneal Cancer | Thymus Cancer | Uterine Cervical Cancer

United States

Search clinical trials for: Bosutinib

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Jordan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations